TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Defining the Clinical Utility of EBV Antibody Screening to Identify Individuals Susceptible to Nasopharyngeal Carcinoma (NPC) Within High-Risk, Multiplex NPC Families

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: OTHER
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
* INCLUSION CRITERIA:~The 2,394 unaffected family members who previously participated in the family study of nasopharyngeal carcinoma (NPC) in Taiwan between 1996 and 2004.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 99 Years
- Healthy Volunteers: f

Study Arms:
- cohort (Type: None): hospital based family cohort

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Assessment of Efficacy and Safety in Relieving Opioid-induced Constipation in Patients With Cancer-related Pain

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Provision of written informed consent prior to any study-specific procedures.~* Men and women aged 18 or older.~* Histologically or cytologically confirmed neoplasm causing pain and requiring management with opioids.~* Self-reported active symptoms of OIC at screening (\<3 RFBMs/week and experiencing \>1 reported symptom of hard/lumpy stools, straining, or sensation of incomplete evacuation/anorectal obstruction in at least 25% of BMs over the previous 4 weeks); and Documented confirmed OIC (\<3 RFBMs/week on average aver the 2-week OIC confirmation period.~* Receiving a stable maintenance opioid regimen consisting of a total daily dose of \>30 mg of oral morphine, or equianalgesic amount(s) of 1 or more opioid therapies for a minimum of 4 weeks prior to screening for cancer-related pain with no anticipated change in opioid dose requirement over the proposed study period as a result of disease progression.~Exclusion Criteria:~* Patients receiving Opioid regimen for treatment of pain other than related to cancer.~* Any condition that may have affected the permeability of the blood-brain barrier, eg, known brain metastases, meningeal metastases, brain injury, multiple sclerosis, recent brain injury, uncontrolled epilepsy.~* Patients with cancer-related pain due to ovarian cancer, leukaemia, or lymphoma are excluded. Patients with multiple myeloma will be allowed.~* Patients requiring radiation therapy between the diaphragm and pelvis 4 weeks prior to Visit 1 (screening) and/or during Part A of the study are excluded. Any patients with suspected clinically relevant radiation-induced injury of small or large intestine are excluded.~* Pregnancy or lactation.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (part A and B) (Type: EXPERIMENTAL): Oral treatment
- 2 (part A and B) (Type: EXPERIMENTAL): Oral treatment
- 3 (part A only) (Type: PLACEBO_COMPARATOR): Oral treatment

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Home Exercise Adherence in Physical Therapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Participants who can read and understand the English language,~* adults between 18-65 years of age,~* have a referral to an outpatient physical therapy clinic for an orthopaedic condition, and~* who own a smartphone with video recording capabilities and available data storage space (at least 500 MB or 0.5 GB).~Exclusion Criteria:~* Individuals referred for non-orthopaedic conditions,~* individuals currently on an established, prescribed home exercise program,~* individuals requiring more than 4 home exercises at one time as part of their rehabilitation program, and~* individuals who do not own a smartphone device with the required storage and recording specifications.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Video Recording Group (Type: EXPERIMENTAL): The experimental group participants will be recorded on their personal smartphone performing their prescribed exercises with individualized instruction from the participating physical therapist. The prescribing therapist will record participants on their own smartphones doing the exercise program in the clinic so that participants can have that video recording of the exercises to help remind them how to do the exercises properly at home. Participants will not be asked to record themselves performing future exercise sessions as documentation of improvement. Intervention: Home Exercise Program and Adherence Logs
- Conventional Printed Group (Type: ACTIVE_COMPARATOR): The active comparator group will receive individualized instruction from the participating physical therapist on how to perform their home exercise program as well as printed instructions of the exercises. No video recording of the control group participants will be performed. Intervention: Home Exercise Program and Adherence Logs

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Collagenase Clostridium Histolyticum for Refractory Iatrogenic Esophageal Strictures

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: EARLY_PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* 18-90 years old~* suffers from dysphagia caused by an iatrogenic esophageal stricture~* the stricture is amenable for endoscopic dilation~* the patient has undergone at least 1 previous endoscopic dilation for the same stricture~* signed the ICF~Exclusion Criteria:~* the patient is not fluent in Dutch

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- local collagenase (Type: EXPERIMENTAL): Patients receiving local injection of collagenase (0.9 mg XiapexR) into the esophageals stricture

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues
Please assess the completion status of the following clinical trial:

Trial Title: Acthar as Rescue Therapy for Transplant Glomerulopathy in Kidney Transplant Recipients

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Kidney transplant recipients with confirmed transplant glomerulopathy on kidney biopsy.~* Failed standard therapy (\>25% reduction in proteinuria) including maximum use of an ACE inhibitor, ARB, or aldosterone blocker with a goal blood pressure less than 130/80 and optimization of their immunosuppression~Exclusion Criteria:~* Diabetes

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Acthar (Type: EXPERIMENTAL): Acthar 80 units twice weekly for 6 months. If endpoint is not reached, duration may be increased to 12 months.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: DORADO-EX: Long-Term Safety Extension Study to the Phase 3 DORADO Study (Protocol DAR-311) of Darusentan in Resistant Hypertension

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects who have completed the Treatment Period of clinical trial DAR-311~* Receiving and adhering to full doses of appropriate guideline-recommended antihypertensive drugs from three different classes of antihypertensive agents, including a diuretic~Exclusion Criteria:~* Subjects who discontinued treatment with study drug prior to the end of the Treatment Period of DAR-311 due to a study drug-related adverse event (AE)~* Treatment with another endothelin receptor antagonist within 6 months of study entry

- Gender: ALL
- Minimum Age: 35 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Darusentan 50 mg (Type: EXPERIMENTAL): Darusentan 50 mg administered orally once daily
- Darusentan 100 mg (Type: EXPERIMENTAL): Darusentan 100 mg administered orally once daily
- Darusentan 300 mg (Type: EXPERIMENTAL): Darusentan 300 mg administered orally once daily

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Testosterone Gel in Preventing Weakness Caused by Steroid Therapy in Men With Glioma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Newly diagnosed high-grade glioma, including the following subtypes:~  * Anaplastic astrocytoma~ * Anaplastic oligodendroglioma~ * Glioblastoma multiforme~* Requires dexamethasone at a dose of \> 4 mg/day to control symptoms of tumor-related edema at time of study enrollment AND has been on a stable dose of steroids for ≥ 5 days prior to study enrollment~* Completed ≥ 80% of prescribed radiotherapy~* Hypogonadal, defined as serum testosterone level \< 350 ng/dL~* No history of prostate or breast cancer~* No benign prostatic hypertrophy requiring therapy OR AUA score of ≥ 8~  * PSA ≤ 4 ng/mL~PATIENT CHARACTERISTICS:~* Karnofsky performance status 60-100%~* Able to keep daily records or has a care provider that agrees to keep daily records of drug administration~* No clinical history of congestive heart failure requiring therapy~* No psychotic disorder requiring active treatment~* No structured exercise program involving exercise for \> 3 hours/week~* No polycythemia (i.e., hematocrit \> 52%)~PRIOR CONCURRENT THERAPY:~* More than 6 months since prior androgen therapy

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 120 Years
- Healthy Volunteers: f

Study Arms:
- Arm 1: Control Group (Type: PLACEBO_COMPARATOR): whey protein powder
- ARM 2 : Treatment Group (Type: ACTIVE_COMPARATOR): Testosterone Gel (10g pouch/day) applied to skin

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Randomized Study Evaluating Ixabepilone Plus Capecitabine or Docetaxel Plus Capecitabine in Metastatic Breast Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Participants with metastatic breast cancer~* Measurable disease~* Up to 1 chemotherapy regimen is acceptable. Participants who have received paclitaxel in the neoadjuvant or adjuvant setting acceptable, only if the last dose of paclitaxel was received 12 months or less before the treatment. There is no timeframe for prior paclitaxel in the metastatic setting.~* Human epidermal growth factor receptor 2-positive participants allowed if they have progressed after receiving treatment with trastuzumab or lapatinib~* Eastern Cooperative Oncology Group Performance status of 0-1~* Age younger than 18 years~* Women of childbearing potential must be using an adequate method of contraception to avoid pregnancy throughout the study and for at least 4 weeks after the last dose of investigational products~Exclusion Criteria:~* More than 1 chemotherapy regimen for the treatment of metastatic breast cancer~* Prior treatment with any epothilone, capecitabine, or docetaxel~* Prior radiation must not have included 30% or more of major bone marrow-containing areas (pelvis, lumbar spine). If prior radiation was less than 30%, a minimum interval of 2 weeks must be allowed between the last radiation treatment and administration of study medication. There must be at least 1 week between focal/palliative radiation and administration of study medication.~* Any current or previous history of brain and/or leptomeningeal metastases~* Neuropathy greater than Grade 2~* Any concurrent malignancy other than nonmelanoma skin cancer or carcinoma in situ of the cervix~* Uncontrolled diabetes mellitus~* Chronic hepatitis~* HIV-positive status~* Administration of trastuzumab, lapatinib, bevacizumab, or other systemic treatment for cancer must be discontinued 28 days prior to study medication. Hormonal anticancer agents must be discontinued at least 14 days prior to study medication. Hormonal replacement therapy is acceptable~* Biphosphonates for palliation of bone metastases allowed if initiated at least 7 days before study entry

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ixabepilone, 40 mg/m^2 + Capecitabine, 1000 mg/m^2 (Type: EXPERIMENTAL): None
- Ixabepilone, 32 mg/m^2 + Capecitabine, 1000 mg/m^2 (Type: EXPERIMENTAL): None
- Docetaxel, 75 mg/m^2 + Capecitabine, 1000 mg/m^2 (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Comparison Between NICOM-Cheetah and Flotrac-Vigileo for Cardiac Output Monitoring.

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients who are deemed to require cardiac output monitoring.~* Patients 21 years old and above~* American Society of Anesthesiologist (ASA) physical status 1 to 4~Exclusion Criteria:~* Patients who are not on mechanical ventilation.~* Patients who are not in sinus rhythm.~* Patients with allergy to adhesive tapes

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- NICOM Cheetah® (Type: None): Patients will be treated as per department protocols and no additional intervention will be performed. Each patient will have an arterial catheter inserted as per our usual practice. All patients will have the FloTrac® connected to the arterial catheter (standard of care in CGH SICU) and the NICOM Cheetah® electrodes placed on the skin across the anterior thoracic wall. The NICOM CO monitor involves the application of non-invasive sensor strips. In this study, it will be applied to patients receiving the FloTrac (standard of care), on top of the standard care of monitoring with Flotrac.
- FloTrac® (Type: None): Same patient population as the NICOM Cheetah® group as described above as all patients will have the FloTrac® connected to the arterial catheter (standard of care in CGH SICU) and the NICOM Cheetah® electrodes placed on the skin across the anterior thoracic wall. The FloTrac CO monitor is the current standard of care for cardiac output monitoring in the SICU of CGH. All patients deemed to require cardiac output monitoring will receive the FloTrac (as per departmental practice).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Extension to CQTI571A2102 to Evaluate Long-term Safety, Tolerability and Efficacy of Imatinib in Severe Pulmonary Arterial Hypertension (PAH)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients who completed in CQTI571A2102 clinical trial including all Study Completion assessments at the end of study visit met the eligibility criteria for that study and did not meet withdrawal criteria for safety reasons during study conduct~Exclusion Criteria:~* Patients with left ventricular ejection fraction (LVEF) \< 45%~* Patients with thrombocytopenia, platelet count \< 50 x109/L (50 x 103/µL).~* Patients with uncontrolled systemic arterial hypertension, systolic pressure \> 160 mmHg or diastolic pressure \> 90 mmHg.~* Patients with a QTcF \> 450 ms for males and \> 470 ms for females in the absence of right bundle branch block.~Other protocol-defined inclusion/exclusion criteria may apply

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- QTI571 (Type: EXPERIMENTAL): Participants received 200 mg or 400 mg every day (qd) based on their highest tolerated dose in CQTI571A2102 (NCT01392469).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of Vancomycin Treatment of Infections Due to Staphylococcus Aureus

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: OTHER
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* 19 years of age or older~* Admitted to an inpatient care unit at The Nebraska Medical Center~* Prescribed intravenous vancomycin therapy with a dosing interval of 24 hours or less~* Vancomycin therapy that lasts for at least 3 doses or 5 half-lives as scheduled with no dosage changes~Exclusion Criteria:~* Estimated creatinine clearance (CrCl) less than 30 ml/min using the Cockroft-Gault equation (in patients over the age of 65 a SCr of 1.0 mg/dL will be assumed for all patients with a reported SCr less than 1.0 mg/dL). Ideal body weight will be used for the Cockroft-Gault equation unless the actual body weight is less than the ideal body weight.~* Patients requiring any form of dialysis~* Pregnancy

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Optimization of Therapeutic Drug Monitoring of Vancomycin in Pediatric Patients With an Implanted Port Catheter

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Pediatric patients with a port catheter~* Treated with systemic vancomycin and/or vancomycin lock~Exclusion Criteria:~* Age \> 18 years~* Active downgrading of care

- Gender: ALL
- Minimum Age: None
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- Patients with port catheter: flushing (Type: EXPERIMENTAL): In patients with a catheter-related blood stream infection (CRBSI) and a port catheter, being treated with vancomycin intravenously, we will flush the catheter with 30 ml of sodium chloride 0.9 % prior to blood sampling to determine vancomycin concentrations, in order to decrease residuel vancomycin in the port.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: A Comparative Study of Patient Satisfaction Between Continued Administration of Previous Antipsychotics Versus Switched Administration to Paliperidone ER in Non-satisfied Patients With Previous Antipsychotic Drug

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Must be diagnosed with schizophrenia according to the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) criteria~* Have taken atypical antipsychotics (aripiprazole, olanzapine, risperidone) at least 6 weeks prior to start of study.~* Have Medication Satisfaction Questionnaire (MSQ) score of ≤3~* Competent patients who manage to answer the questionnaires~Exclusion Criteria:~* Have had a history or current symptoms of tardive dyskinesia or neuroleptic malignant syndrome~* Have had relevant history of or current presence of any significant or unstable cardiovascular, respiratory, neurological (including seizures or significant cerebrovascular), renal, hepatic, hematologic, endocrine, immunologic, morbid obesity (BMI≥40), or other systemic disease~* Had received two or more different kind of antipsychotics.~* Had a history of taking paliperidone extended release (ER).~* Allergy or hypersensitivity to risperidone or paliperidone ER.~* Have been on clozapine or long-acting injectable antipsychotic medication during the last 3 months.~* Have had Medication Satisfaction Questionnaire (MSQ) score\>3~* Have been hospitalized for longer than 8 continuous weeks during the past 6 months~* Had history of any severe preexisting gastrointestinal narrowing (pathologic or iatrogenic) or inability to swallow the oral tolerability medication whole with the aid of water for patients requiring oral tolerability testing~* Current substance dependence (DSM-IV) or past history of dependence (more than 6 months)

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Paliperidone ER (Type: EXPERIMENTAL): Immediate initiation of Paliperidone ER for a total of 12 weeks
- Antipsychotics and paliperidone ER (Type: EXPERIMENTAL): Delayed initiation included previous atypical antipsychotics for 8 weeks and then be initiated on paliperidone ER at Day 56 for 4 weeks. The atypical antipsychotics includes aripiprazole, olanzapine and risperidone. These antipsychotics belongs to the class of second generation bipolar atypical antipsychotics.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues